RxDoctor Payments Data

Charinale Prado, NP

Nurse Practitioner · Flagstaff, AZNPI 1700212271

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,400 of the $15,083 with a category attached, or 88.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 7.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,083in general payments, 2019–2025

Across 619 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Johnson & Johnson$972
  • Incyte Corporation$850
  • Pfizer$795
  • Merck$790
  • Novartis$690
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$13,40089%
  • Education$1,68311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)49$1,177
Johnson & Johnson39$972
Incyte Corporation24$850
Pfizer37$795
Merck31$790
Novartis35$690
Lilly USA, LLC24$675
Seagen Inc.20$639
Bristol Myers Squibb36$483
Genentech USA, Inc.17$448
Sanofi18$439
E.r. Squibb & Sons, L.L.C.22$438
AVEO Pharmaceuticals, Inc.11$391
Gilead(2 entities)14$355
Daiichi Sankyo Inc.13$353
Astellas Pharma US Inc12$349
Bayer15$298
Pharmacosmos Therapeutics Inc.10$297
Amgen14$276
Takeda Pharmaceuticals U.S.A., Inc.7$272
AbbVie11$271
Eisai Inc.12$263
Sanofi-aventis U.S. LLC3$220
GSK9$204
Sobi, Inc9$201
Genmab U.S., Inc.8$183
Puma Biotechnology, Inc.7$155
Progenics Pharmaceuticals, Inc.4$149
Karyopharm Therapeutics Inc.5$140
Regeneron Healthcare Solutions, Inc.5$139
Stemline Therapeutics Inc.4$131
Pharmacyclics LLC, An Abbvie Company5$119
Array Biopharma Inc7$113
EMD Serono, Inc.5$109
Mirati Therapeutics, Inc.5$102
Servier Pharmaceuticals LLC4$93
Geron Corporation3$92
Tersera Therapeutics LLC3$90
Ipsen Biopharmaceuticals, Inc5$80
Beigene USA, Inc.3$80
Rigel Pharmaceuticals, Inc.4$78
Alnylam Pharmaceuticals Inc.3$77
Coherus Oncology, Inc.3$71
Blueprint Medicines Corporation3$71
Boehringer Ingelheim3$68
Adaptive Biotechnologies Corporation3$67
Deciphera Pharmaceuticals Inc.3$66
Kyowa Kirin, Inc.4$63
Jazz Pharmaceuticals Inc.2$60
Beone Medicines USA, Inc.2$60
ADC Therapeutics America, Inc.2$54
Legend Biotech USA Inc.2$42
CTI Biopharma Corp.2$39
Immunocore Limited2$38
Sun Pharmaceutical Industries Inc.2$34
Taiho Oncology, Inc.1$31
Nuvation Bio Inc.1$28
Sumitomo Pharma America, Inc.1$25
Dendreon Pharmaceuticals LLC1$23
Digestive Care, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,083 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$507,181
Medicare patients
305
Services billed
12,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib14$329,666
IbrancePalbociclib12$189,242
Abiraterone Acetate13$18,195
Imatinib Mesylate12$12,065
EliquisApixaban16$10,571
Exemestane19$5,036
Morphine Sulfate ErMorphine Sulfate22$2,287
Hydroxyurea38$1,233
Anastrozole59$1,120
Raloxifene Hcl26$1,087
Letrozole40$863
Tamoxifen Citrate21$603
Albuterol Sulfate HfaAlbuterol Sulfate18$596
Acyclovir29$459
Potassium Chloride12$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$119$329,66614 claims
PfizerIbrance, Eliquis$795$199,81328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Flagstaff

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →